Protalix BioTherapeutics (PLX) Retained Earnings (2010 - 2025)
Protalix BioTherapeutics (PLX) posted quarterly Retained Earnings of -$385.0 million for Q4 2025, down 1.75% year-over-year from -$391.8 million in Q4 2024, and down 1.75% quarter-over-quarter from -$378.4 million in Q4 2024.
Protalix BioTherapeutics (PLX) Retained Earnings (2010 - 2025) Analysis & Trends
Protalix BioTherapeutics' Retained Earnings history runs 16 years deep, the most recent figure standing at -$385.0 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 1.75% year-over-year to -$385.0 million; the TTM figure through Dec 2025 stood at -$385.0 million (down 1.75% YoY), while the FY2025 annual figure was -$385.0 million, down 1.75% from the prior year.
- Retained Earnings for Q4 2025 stood at -$385.0 million, down from -$378.4 million in the prior quarter.
- The five-year high for Retained Earnings was -$374.9 million in Q4 2021, with the low at -$389.9 million in Q4 2022.
- The 5-year median for Retained Earnings is -$381.5 million (2023), against an average of -$381.9 million.
- The sharpest annual moves came in 2021 and 2023: Retained Earnings slipped 7.94% in 2021, then grew 2.13% in 2023.
- Protalix BioTherapeutics' Retained Earnings stood at -$374.9 million in 2021, then retreated by 3.98% to -$389.9 million in 2022, then gained by 2.13% to -$381.5 million in 2023, then gained by 0.83% to -$378.4 million in 2024, then decreased by 1.75% to -$385.0 million in 2025.
- Business Quant data shows PLX's Retained Earnings at -$385.0 million in Q4 2025, -$378.4 million in Q4 2024, and -$381.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -385.00 Mn |
| Dec 31, 2024 | -378.39 Mn |
| Dec 31, 2023 | -381.55 Mn |
| Dec 31, 2022 | -389.86 Mn |
| Dec 31, 2021 | -374.93 Mn |
| Dec 31, 2020 | -347.35 Mn |
| Dec 31, 2019 | -340.83 Mn |
| Dec 31, 2018 | -322.55 Mn |
| Dec 31, 2017 | -296.10 Mn |
| Dec 31, 2016 | -212.66 Mn |
| Dec 31, 2015 | -183.29 Mn |
| Dec 31, 2014 | -241.33 Mn |
| Dec 31, 2013 | -211.39 Mn |
| Dec 31, 2012 | -183.60 Mn |
| Dec 31, 2011 | -171.98 Mn |
| Dec 31, 2010 | -135.45 Mn |